

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

ENDO PHARMACEUTICALS HOLDINGS INC
Form 8-K
November 20, 2001

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):
November 20, 2001 (November 19, 2001)

ENDO PHARMACEUTICALS HOLDINGS INC.

(Exact name of registrant as specified in its charter)

DELAWARE	39040	13-4022871
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Painters Drive Chadds Ford, Pennsylvania	19317
-----	-----
(Address of principal executive offices)	(Zip Code)

(610) 558-9800

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

Exhibit Number	Description
----------------	-------------

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

99.1 Press release issued by Endo Pharmaceuticals Holdings Inc. on November 19, 2001

Item 9. Regulation FD Disclosure.

On November 19, 2001, the Registrant issued a press release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)

By: /s/ CAROL A. AMMON

Name: Carol A. Ammon
Title: President & Chief Executive Officer

Dated: November 20, 2001

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press release issued by Endo Pharmaceuticals Holdings Inc. on November 19, 2001

Exhibit 99.1

Contact: Robert Siegfried/Jeremy Fielding
Kekst and Company
212-521-4800

ENDO PHARMACEUTICALS ANNOUNCES
CLOSING OF OVER-ALLOTMENT SHARES

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 8-K

Chadds Ford, PA, November 19, 2001 - Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP and ENDPW) announced today that it had closed the sale of an additional 1,525,000 shares of common stock, at \$8.00 per share, issued by the Company in connection with the exercise by the underwriters in the Company's recent public offering of their over-allotment option. The recent public offering was underwritten through an underwriting syndicate led by JP Morgan and Salomon Smith Barney, together with co-managers, SG Cowen and Wachovia Securities. Including the shares issued today, a total of 12,925,000 shares common stock were issued and sold by the Company in this transaction.

Endo, through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc., is a fully integrated specialty pharmaceutical company with market leadership in pain management. The company is engaged in the research, development, sales and marketing of both branded and generic pharmaceutical products primarily for the treatment of pain.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities. A Prospectus relating to these securities may be obtained from JP Morgan at 60 Wall Street, New York, NY 10260 or Salomon Smith Barney at 388 Greenwich Street, 32nd Floor, New York, NY 10013.

###